Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination
β Scribed by A. Roux; A. Liboux; B. Delhotal; J. Gaillot; B. Flouvat
- Publisher
- Springer
- Year
- 1983
- Tongue
- English
- Weight
- 462 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Diltiazem and hydrochlorothiazide are widely used to treat cardiovascular disease, often in combination. The purpose of this investigation was to determine whether a drug -drug pharmacokinetic interaction exists between diltiazem and hydrochlorothiazide. In a randomized, crossover, open study, multi
The bioavailability and pharmacokinetics of 10 mg of mepindolol sulphate and of 25 mg df hydrochlorothiazide were compared in a cross-over design in five healthy volunteers after the administration of either the single drugs (Corindolan@ and Esidrix@) or in combination (Tenesor@). Maximum concentra
The chiral beta-blocker acebutolol (AC) is marketed as a racemic mixture. Both AC and its major metabolite, diacetotol (DC), are chiral, the S-enantiomer possessing beta-blocking activity. The pharmacokinetics of AC and DC enantiomers was determined in 12 healthy subjects following oral administrati
Acebutolol (AC) is a chiral b-blocker which is extensively metabolized to an active, chiral metabolite, diacetolol (DC). Similar to some other b-adrenoceptors, AC exhibits multiple peaks in plasma concentrationΒ±time curves after oral doses to humans. We examined the suitability of the rat as an anim